The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOCs). Therapeutic resistance, resulting from restoration of homologous recombination (HR) repair or replication fork stabilization, is a pressing clinical problem. We asses...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Clin Cancer Res
मुख्य लेखकों: Parmar, Kalindi, Kochupurakkal, Bose S., Lazaro, Jean-Bernard, Wang, Zhigang C., Palakurthi, Sangeetha, Kirschmeier, Paul T., Yang, Chunyu, Sambel, Larissa A., Farkkila, Anniina, Reznichenko, Elizaveta, Reavis, Hunter D, Dunn, Connor E., Zou, Lee, Do, Khanh T., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Liu, Joyce F., D’Andrea, Alan D., Shapiro, Geoffrey I.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2019
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6801076/
https://ncbi.nlm.nih.gov/pubmed/31409614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0448
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन